leadf
logo-loader
viewProactive Group

Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings

Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings

1508771876_squireel_and_peanut.png
Not everyone can tolerate peanuts out there

Shares in Aimmune Therapeutics (NASDAQ:AIMT) raced up nearly 30% in New York on Monday in response to the announcement from DBV Technologies' (NASDAQ:DBVT) over its peanut allergy treatment.

Meanwhile, shares in the latter plunged over 46% to US$26.21 to be the worst performer on Nasdaq on Monday. Aimmune Therapeutics on the other hand raced up to US$33.23 each.

Viaskin Peanut,  the DBV treatment, reportedly failed to demonstrate sufficient efficacy in a pivotal phase III trial.

The trial was evaluating the safety and efficacy of Viaskin Peanut in children four to 11 years.

Topline results showed a statistically significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin Peanut 250 µg after 12 months of treatment as compared to 13.6% of patients in the placebo arm.

However, the primary endpoint did not reach the point as had been proposed in the study's Statistical Analysis Plan (SAP) submitted to the US FDA.

Aimmune's lead candidate is an orally administered biologic that desensitizes patients with peanut allergy.

A Phase 3 study, PALISADE, is ongoing with an estimated completion date of September 2018.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Mountain Valley MD to start husbandry animal trials to validate company’s...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company is planning to start husbandry animal trials with a third-party research organization to validate injectable solubilized Ivermectin...

11 minutes ago

2 min read